Acromegaly Market - A Global and Regional Analysis: Focus on Drug Class, and Regional Analysis - Analysis and Forecast, 2025-2035

The global acromegaly market is currently in the growth stage of its lifecycle, driven by significant advancements in the diagnosis and treatment of the disease. Although acromegaly remains a rare disease, its increasing prevalence and improved diagnostic capabilities have led to greater identification and awareness of the disease. This has boosted the demand for effective treatments. The approval of innovative therapies, such as long-acting somatostatin analogs and growth hormone receptor antagonists, has significantly enhanced disease management, improving patient outcomes and fueling the demand for acromegaly therapies.

Furthermore, the growing focus on personalized medicine and the expansion of healthcare access in emerging markets are opening up new growth avenues. The increasing awareness among healthcare providers and patients is also contributing to the expansion of the global acromegaly market. However, challenges such as the high cost of treatments and misdiagnosis are expected to hinder the growth of the global acromegaly market.

Impact

• Increasing demand for acromegaly therapies is anticipated to support the growth of the global acromegaly market during the forecast period 2025-2035.
• The global acromegaly market is expected to grow at a significant rate due to advancements in diagnostic technologies, the development of innovative therapies, and increasing awareness among patients and healthcare providers.

Market Segmentation:

Segmentation 1: by Drug Class

• Somatostatin Analogues (SSAs)
• Growth Hormone Receptor Antagonists (GHRAs)
• Others

Segmentation 2: by Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Rest-of-the-World

North America is expected to dominate the global acromegaly market during the forecast period due to its advanced healthcare infrastructure, high prevalence, and increased awareness of the disease. The region also benefits from regulatory advantages and a strong pharmaceutical presence, which accelerates the availability of effective treatments and drives the growth of the global acromegaly market.

Recent Developments in the Global Acromegaly Market

• Regulatory Activities: In March 2025, Crinetics Pharmaceuticals announced the European Medicines Agency (EMA) validation of the Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in the treatment of acromegaly.
• Product Launches: In October 2024, Teva Pharmaceutical Industries Ltd. announced the launch of the first and only generic version of Sandostatin® LAR Depot in the U.S.
• Regulatory Activities: In May 2024, Cipla received U.S. FDA approval to market Lanreotide injection in the U.S.

Demand - Drivers and Limitations

The following are the drivers for the global acromegaly market:

• Rising Prevalence of Acromegaly
• Continuous Advancements in Treatment Options
• Growing Healthcare Investment in Rare Diseases

The global acromegaly market is expected to face some limitations too, due to the following challenges:

• High Treatment Costs
• Limited Awareness in the Underdeveloped Regions and Misdiagnosis of the Disease

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: Product launches and innovations in the global acromegaly market are focused on advancing treatment options to improve patient care. These innovations aim to enhance the efficacy of therapies and streamline the detection and management of the disease. Key players in the market, such as Merck, and Enanta Pharmaceuticals, have been involved in the development of therapies for acromegaly.

Competitive Strategy: Enterprises led by market leaders in the global acromegaly market are continuously working on updating their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players in the global acromegaly market has been conducted, providing insights into how these companies compare in terms of product offerings, market share, and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

• Novartis AG
• Sun Pharmaceutical Industries Ltd
• Ipsen Pharma
• Chiasma, Inc.
• Peptron, Inc.
• Crinetics Pharmaceuticals Inc.
• Camurus
• Ionis Pharmaceuticals, Inc.
• Dauntless Pharmaceuticals
• Immunwork, Inc.
• Cipla
• Teva Pharmaceutical Industries Ltd.

This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.